Neurological Adverse Events Associated With Immune Checkpoint Inhibitors Identified Through Disproportionality Analysis of the FDA Adverse Event Reporting System
Cancer Medicine · 2026
DOI: 10.1002/cam4.72206 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Tao Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Adverse Drug Reaction Reporting Systems, Nervous System Diseases, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chongqing Medical University.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Neurological immune‐related adverse events (N‐irAEs) from immune checkpoint inhibitors (ICIs) are rare but potentially fatal. This study aimed to characterize their real‐world profile to support early detection and management.
Methods
We analyzed ICI‐associated individual case safety reports (ICSRs) in the FDA Adverse Event Reporting System (FAERS) from April 2011 to June 2023. Disproportionality analyses used the reporting odds ratio (ROR) and the Bayesian confidence propagation neural network (BCPNN). Associations between serious N‐irAEs and sex or age group (< 60 vs. ≥ 60 years) were assessed using chi‐squared tests. We also evaluated the co‐occurrence of myasthenia gravis with myositis and/or myocarditis and its association with mortality.
Results
A total of 3486 ICSRs involving N‐irAEs were identified, with 550 cases reporting fatal outcomes. A total of 4139 N‐irAE signals were detected; among these, 2560 signals corresponded to the top 10 Preferred Terms (PTs) with the highest reporting frequencies. The median time from ICI initiation to the onset of N‐irAEs was 82 days (IQR: 29–219 days). Of the 4139 N‐irAE signals, 1925 (46.5%) were classified as serious adverse events; no statistically significant differences were observed in their distribution by sex ( χ 2 = 2.492, p = 0.114) or age ( χ 2 = 2.946, p = 0.086). A total of 461 cases of myasthenia gravis were identified, of which 219 (47.5%) were concomitant with myocarditis and/or myositis. Among the 137 fatal cases of myasthenia gravis, 70 (51.1%) were concomitant with myocarditis and/or myositis.
Conclusion
This study offers a comprehensive characterization of N‐irAEs, highlights the fatality risk when myasthenia gravis co‐occurs with myocarditis and/or myositis, and underscores the importance of early recognition, multi‐system evaluation, and timely intervention to improve patient safety and optimize the risk–benefit balance of immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Chongqing Medical University, Chongqing, China.
- Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- College of Pharmacy, Chongqing Medical University, Chongqing, China.
ORCID-Profile: Kexin Shu, Hongyi Xiao, Yonghua Yuan, Fujun Zhang, Yu Liu
Förderung
- Chongqing Medical University
Zitieren
APA
Chen, T., Shu, K., Xiao, H., Yuan, Y., Zhang, F., & Liu, Y. (2026). Neurological Adverse Events Associated With Immune Checkpoint Inhibitors Identified Through Disproportionality Analysis of the FDA Adverse Event Reporting System. Cancer Medicine. https://doi.org/10.1002/cam4.72206
Vancouver
Chen T, Shu K, Xiao H, Yuan Y, Zhang F, Liu Y. Neurological Adverse Events Associated With Immune Checkpoint Inhibitors Identified Through Disproportionality Analysis of the FDA Adverse Event Reporting System. Cancer Medicine. 2026. doi:10.1002/cam4.72206
BibTeX
@article{Chen2026,
author = {Chen, Tao and Shu, Kexin and Xiao, Hongyi and Yuan, Yonghua and Zhang, Fujun and Liu, Yu},
title = {Neurological Adverse Events Associated With Immune Checkpoint Inhibitors Identified Through Disproportionality Analysis of the FDA Adverse Event Reporting System},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.72206}
}
EUVIMED